Seelos Therapeutics selected by U.S. Army to evaluate SLS-002 in PTSD
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 24 2024
0mins
Collaboration with U.S. Army: Seelos Therapeutics has entered into a Material Transfer Agreement with the U.S. Army Medical Materiel Development Activity to provide SLS-002, an intranasal racemic ketamine, for a clinical trial aimed at treating PTSD in military personnel and veterans.
Trial Details: The Phase II study will assess the safety, tolerability, and efficacy of various treatments for PTSD, with dosing expected to start before the end of 2024, and will include monitoring for suicidal thoughts and behaviors as well as evaluating biomarkers related to PTSD.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
